Clinical Trial Considerations for eBC Treatment Selection

Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2– early-stage breast cancer (eBC) guide clinical decision-making, exploring real-world adherence to these guidelines, the complexity of risk stratification in various clinical scenarios, and the role of clinical factors, biomarkers, and advanced testing methodologies (including RSClin N+, next-generation sequencing [NGS], fluorescence in situ hybridization [FISH], immunohistochemistry [IHC], and circulating DNA [ctDNA]) in defining “high-risk” patients and guiding treatment strategies.

EP: 1.Introduction and HR+/HER2– eBC Overview

EP: 2.Approaches to eBC Diagnosis and Risk Stratification

EP: 3.CDK4/6 Inhibitors Treatment Options in the eBC Setting

Now Viewing

EP: 4.Clinical Trial Considerations for eBC Treatment Selection

Video content above is prompted by the following:

1. How do you use adjuvant therapy in patients with HR+/HER2–eBC?
   1. How do risk factors impact your adjuvant treatment strategy?
      1. Which risk factors are most influential, and why?
   2. Please discuss some recent adjuvant CDK4/6 inhibitor studies in eBC:
      1. Abemaciclib + endocrine therapy
      2. Ribociclib + nonsteroidal aromatase inhibitor — Final analysis Node-negative (N0) subgroup analysis; NATALEE 4-y
      3. Palbociclib – analysis of the sensitivity to endocrine therapy assay in the PALLAS adjuvant trial of palbociclib Original PALLAS

Related Videos